WuXi Biologics MFG8 facility clears FDA Pre-License Inspection
- MFG8 passed the FDA Pre‑License Inspection, supporting commercial manufacturing for a potential blockbuster autoimmune therapy.
- The seven‑day inspection was conducted by three FDA inspectors and reviewed the facility's quality management system and drug substance processes.
- MFG8 houses twelve 4,000L single‑use bioreactors and employs a scale‑out model to provide commercial manufacturing from 4,000L to 20,000L.
- As of end‑2025, WuXi Biologics reported 46 regulatory inspections (22 by FDA and EMA), 136 facility license approvals and a 100% FDA PLI pass rate.
FDA clearance for commercial supply
The MFG8 drug substance facility in Hebei has passed the U.S. FDA Pre‑License Inspection, enabling commercial manufacturing support for a potential blockbuster autoimmune therapy. The seven‑day inspection involved three FDA inspectors and covered the facility’s quality management system and drug substance manufacturing processes.
Facility capacity and sustainability features
MFG8 is equipped with twelve 4,000L single‑use bioreactors and follows a scale‑out strategy to offer commercial manufacturing at scales ranging from 4,000L to 20,000L. The site incorporates sustainable construction practices, digital platforms and a rooftop photovoltaic system to advance carbon reduction, resource reuse and recycling.
Regulatory context and network role
MFG8 is part of WuXi Biologics’ global manufacturing network. The company reported passing 46 regulatory inspections, including 22 conducted by FDA and EMA, securing 136 facility license approvals and maintaining a 100% pass rate for FDA Pre‑License Inspections; it also cited more than 1,800 GMP quality audits (including over 230 by EU Qualified Persons) and operation of 25 drug substance and 18 drug product facilities.
Source: WuXi
